TSK&F invests in R&D to boost bottom line

TSK&F, a major pharmaceutical company, yesterday forecast its sales of over-the-counter medicines in China will post "explosive" growth in the next decade, as it introduces more drugs tailored to the local market.

"The growth rate will be double the market average by at least 15 percent in the next 10 years," said Danny Ng, general manager of TSK&F, a subsidiary of pharmaceutical giant GlaxoSmithKline (GSK).

TSK&F also announced yesterday that it set up a research and development (R&D) center in China, the fifth of its kind for GSK worldwide. The other four are located in the US, the UK, India and Germany.